Immunocore - BIO Deutschland

More documents

Recommendations

Info

Company history Oxford University Company formed 1999 Avidex Venture backed company 1999 - 2006 MediGene AG Acquired Avidex September 2006 Immunocore Spinout October 2008 Immunocore
Summary ● The company focuses on making T cell receptors which are • Soluble • High affinity • Able to target intracellular antigens ● Dominant ip and know-how from 10 years of research ● Development candidate in progress Immunocore
Page 1: Immunocore Limited 3 rd European Bu
Page 5 and 6: Breaking immune tolerance to cancer
Page 7 and 8: Cell antigen targeting by mAbs and
Page 9 and 10: High affinity mTCRs target where na
Page 11 and 12: Cancer cells avoid T cell activatio
Page 13 and 14: Creating a product Immunocore
Page 15 and 16: Key features of in vitro data ● N
Page 17 and 18: EBV-specific T cells redirected by
Page 19 and 20: Mechanism of Action: anti-CD3 avidi
Page 21 and 22: Melan A efficacy study (naturally p
Page 23 and 24: CAM003 - Melan-A TCR stimulates PBM
Page 25 and 26: Monoclonal TCR Pipeline Antigen tar
Page 27: Immunocore Limited 3 rd European Bu

Immunocore - BIO Deutschland

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?